Inhibitors | Comment | Organism | Structure |
---|---|---|---|
Azathioprine | IC50: 0.43-0.532 mM | Homo sapiens | |
Furosemide | IC50: 0.015-0.019 mM, has the potential to inhibit thiopurine S-methyltransferase in patients with chronic inflammatory bowel disease | Homo sapiens | |
piretanide | IC50: 0.3-0.313 mM | Homo sapiens | |
testosterone | IC50: 0.03-0.072 mM | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
erythrocyte | from patients with chronic inflammatory bowel disease | Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
S-adenosyl-L-methionine + 6-thioguanine | - |
Homo sapiens | S-adenosyl-L-homocysteine + 6-methylthioguanine | - |
? |
Synonyms | Comment | Organism |
---|---|---|
TPMT | - |
Homo sapiens |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.015 | 0.019 | IC50: 0.015-0.019 mM, has the potential to inhibit thiopurine S-methyltransferase in patients with chronic inflammatory bowel disease | Homo sapiens | Furosemide | |
0.03 | 0.072 | IC50: 0.03-0.072 mM | Homo sapiens | testosterone | |
0.3 | 0.313 | IC50: 0.3-0.313 mM | Homo sapiens | piretanide | |
0.43 | 0.532 | IC50: 0.43-0.532 mM | Homo sapiens | Azathioprine |